Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308562 | 0.92 | MEN1 (0.52) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL532526 | 0.91 | MEN1 (0.67) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL12755327 | 0.91 | MEN1 (0.67) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL532527 | 0.91 | MEN1 (0.67) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL12352444 | 0.91 | MEN1 (0.67) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL13018205 | 0.91 | SLC28A1 (0.52) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL15276409 | 0.91 | SLC28A1 (0.52) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL15497392 | 0.91 | SLC28A1 (0.52) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL16452370 | 0.91 | SLC28A1 (0.52) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL18852608 | 0.91 | SLC28A1 (0.52) | P2RY2LMNATHRBSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | MEN1 2522/4885USP2 2311/4885POLB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.